 |
|
|
| |
Phase 1b/2a study of heterologous ChAdOx1-HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB on nucleos(t)ide analogues
|
| |
| |
EASL 2022 June 22-26 London
T Evans1, L Bussey1, SL Teo2, A Tria2, A Brown3, R Mehta1, K Anderson1, A Vardeu1, WL Chuang4, CC Yi5, YS Lim6, TW Young7, K Agarwal8, S Ryder9, J Heo10, BK Jang11, WY Tak12, SH Ahn13, CY Chen14, GH Lo15, KC Tseng16, W Kim17, SK Yoon18, WW Su19, CT Hu20, E Barnes3
1Vaccitech, 2ICON, 3Oxford University, Affiliations, 4Kaohsiung Medical University Chung-Ho Memorial Hospital, 6Asan Medical Center, 8King's College Hospital NHS Foundation Trust, 9Nottingham University Hospitals NHS Trust, 10Pusan National University Hospital, 11Keimyung University Dongsan Hospital , 12Kyungpook National University Hospital, 13Yonsei University College of Medicine, 14Chia-Yi Christian Hospital, 15E-Da Hospital, 16Dalin Tzu Chi General Hospital, 17Seoul Metropolitan Government Seoul National University Boramae Medical Center, 18Catholic University of Korea Seoul Saint Mary's Hospital, 19Changhua Christian Hospital, 20Hualien Tzu Chi Hospital
link to reports
HBV at EASL 2022
|
| |
|
|
|
|
|
